Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Phospholipase A2 receptor-associated membranous nephropathy in a patient with IgG4-related disease: A case report.

Muhsin SA, Masia R, Smith RN, Wallace ZS, Perugino CA, Stone JH, Niles JL, Cortazar FB.

Medicine (Baltimore). 2019 May;98(20):e15616. doi: 10.1097/MD.0000000000015616.

2.

Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome.

Cortazar FB, Rosenthal J, Laliberte K, Niles JL.

Clin Kidney J. 2018 Jul 24;12(2):224-231. doi: 10.1093/ckj/sfy067. eCollection 2019 Apr.

3.

Renal Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Zonozi R, Niles JL, Cortazar FB.

Rheum Dis Clin North Am. 2018 Nov;44(4):525-543. doi: 10.1016/j.rdc.2018.06.001. Epub 2018 Sep 7. Review.

PMID:
30274621
4.

Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System.

Wallace ZS, Wallwork R, Zhang Y, Lu N, Cortazar F, Niles JL, Heher E, Stone JH, Choi HK.

Ann Rheum Dis. 2018 Sep;77(9):1333-1338. doi: 10.1136/annrheumdis-2018-213452. Epub 2018 May 14.

5.

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

Cortazar FB, Muhsin SA, Pendergraft WF 3rd, Wallace ZS, Dunbar C, Laliberte K, Niles JL.

Kidney Int Rep. 2017 Nov 14;3(2):394-402. doi: 10.1016/j.ekir.2017.11.004. eCollection 2018 Mar.

6.

Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.

Miloslavsky EM, Niles JL, Wallace ZS, Cortazar FB, Fernandes A, Laliberte K, Stone JH.

Semin Arthritis Rheum. 2018 Oct;48(2):288-292. doi: 10.1016/j.semarthrit.2018.01.013. Epub 2018 Feb 3.

PMID:
29530330
7.

Subglottic Stenosis in Granulomatosis With Polyangiitis: The Role of Laryngotracheal Resection.

Costantino CL, Niles JL, Wright CD, Mathisen DJ, Muniappan A.

Ann Thorac Surg. 2018 Jan;105(1):249-253. doi: 10.1016/j.athoracsur.2017.07.026. Epub 2017 Nov 1.

PMID:
29100647
8.

Reply.

Cortazar FB, Niles JL.

Arthritis Rheumatol. 2017 Oct;69(10):2095-2096. doi: 10.1002/art.40210. Epub 2017 Aug 15. No abstract available.

9.

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.

Cortazar FB, Leaf DE, Owens CT, Laliberte K, Pendergraft WF 3rd, Niles JL.

BMC Nephrol. 2017 Feb 1;18(1):44. doi: 10.1186/s12882-017-0459-z.

10.

Effect of Continuous B Cell Depletion With Rituximab on Pathogenic Autoantibodies and Total IgG Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Cortazar FB, Pendergraft WF 3rd, Wenger J, Owens CT, Laliberte K, Niles JL.

Arthritis Rheumatol. 2017 May;69(5):1045-1053. doi: 10.1002/art.40032. Epub 2017 Mar 31.

11.

Nephrotoxic effects of common and emerging drugs of abuse.

Pendergraft WF 3rd, Herlitz LC, Thornley-Brown D, Rosner M, Niles JL.

Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1996-2005. doi: 10.2215/CJN.00360114. Epub 2014 Jul 17. Review. Erratum in: Clin J Am Soc Nephrol. 2019 Apr 5;14(4):586.

12.

Case records of the Massachusetts General Hospital. Case 21-2014. A 68-year-old man with a sudden onset of diplopia.

Venna N, Niles JL, Lev MH, Frosch MP.

N Engl J Med. 2014 Jul 10;371(2):162-73. doi: 10.1056/NEJMcpc1403308. No abstract available.

PMID:
25006723
13.

Long-term maintenance therapy using rituximab-induced continuous B-cell depletion in patients with ANCA vasculitis.

Pendergraft WF 3rd, Cortazar FB, Wenger J, Murphy AP, Rhee EP, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2014 Apr;9(4):736-44. doi: 10.2215/CJN.07340713. Epub 2014 Mar 13.

14.

Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis.

Pendergraft WF 3rd, Niles JL.

Curr Opin Rheumatol. 2014 Jan;26(1):42-9. doi: 10.1097/BOR.0000000000000014. Review.

PMID:
24276086
15.

Fetal outcomes after rituximab exposure in women with autoimmune vasculitis.

Pendergraft WF 3rd, McGrath MM, Murphy AP, Murphy P, Laliberte KA, Greene MF, Niles JL.

Ann Rheum Dis. 2013 Dec;72(12):2051-3. doi: 10.1136/annrheumdis-2013-203833. Epub 2013 Jul 17. No abstract available.

16.

Continuous renal replacement therapy outcomes in acute kidney injury and end-stage renal disease: a cohort study.

Allegretti AS, Steele DJ, David-Kasdan JA, Bajwa E, Niles JL, Bhan I.

Crit Care. 2013 Jun 20;17(3):R109. doi: 10.1186/cc12780.

17.

Contaminated cocaine and antineutrophil cytoplasmic antibody-associated disease.

McGrath MM, Isakova T, Rennke HG, Mottola AM, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2011 Dec;6(12):2799-805. doi: 10.2215/CJN.03440411. Epub 2011 Oct 6.

18.

Antineutrophil cytoplasmic antibodies, autoimmune neutropenia, and vasculitis.

Grayson PC, Sloan JM, Niles JL, Monach PA, Merkel PA.

Semin Arthritis Rheum. 2011 Dec;41(3):424-33. doi: 10.1016/j.semarthrit.2011.02.003. Epub 2011 Apr 19.

19.

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis.

Rhee EP, Laliberte KA, Niles JL.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1394-400. doi: 10.2215/CJN.08821209. Epub 2010 May 24.

20.

Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known.

de Lind van Wijngaarden RA, van Rijn L, Hagen EC, Watts RA, Gregorini G, Tervaert JW, Mahr AD, Niles JL, de Heer E, Bruijn JA, Bajema IM.

Clin J Am Soc Nephrol. 2008 Jan;3(1):237-52. Epub 2007 Dec 12. Review.

21.

Choice of replacement solution and anticoagulant in continuous venovenous hemofiltration.

Palsson R, Laliberte KA, Niles JL.

Clin Nephrol. 2006 Jan;65(1):34-42.

PMID:
16429840
22.

Prevalence of antineutrophil cytoplasmic antibodies in patients with various pulmonary diseases or multiorgan dysfunction.

Vassilopoulos D, Niles JL, Villa-Forte A, Arroliga AC, Sullivan EJ, Merkel PA, Hoffman GS.

Arthritis Rheum. 2003 Apr 15;49(2):151-5.

23.

Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis.

Han WK, Choi HK, Roth RM, McCluskey RT, Niles JL.

Kidney Int. 2003 Mar;63(3):1079-85.

24.
25.

Evaluation and treatment of vasculitis in the critically ill patient.

Merkel PA, Choi HK, Niles JL.

Crit Care Clin. 2002 Apr;18(2):321-44. Review.

PMID:
12053837
27.
28.

A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS).

Stone JH, Hoffman GS, Merkel PA, Min YI, Uhlfelder ML, Hellmann DB, Specks U, Allen NB, Davis JC, Spiera RF, Calabrese LH, Wigley FM, Maiden N, Valente RM, Niles JL, Fye KH, McCune JW, St Clair EW, Luqmani RA; International Network for the Study of the Systemic Vasculitides (INSSYS).

Arthritis Rheum. 2001 Apr;44(4):912-20.

29.

Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis.

Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Shah S, Bousvaros A, Ransil B, Wild G, Cohen A, Edwardes MD, Stevens AC.

Gastroenterology. 2001 Jan;120(1):13-20.

PMID:
11208709
30.

Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine.

Choi HK, Slot MC, Pan G, Weissbach CA, Niles JL, Merkel PA.

Arthritis Rheum. 2000 Nov;43(11):2488-92.

32.

Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies.

Choi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA.

Arthritis Rheum. 2000 Jan;43(1):226-31. Review.

33.

Anticoagulation in continuous renal replacement therapy.

Abramson S, Niles JL.

Curr Opin Nephrol Hypertens. 1999 Nov;8(6):701-7. Review.

PMID:
10630816
35.

Interaction of purified human proteinase 3 (PR3) with reconstituted lipid bilayers.

Goldmann WH, Niles JL, Arnaout MA.

Eur J Biochem. 1999 Apr;261(1):155-62.

36.

Alternating antineutrophil cytoplasmic antibody specificity: drug-induced vasculitis in a patient with Wegener's granulomatosis.

Choi HK, Merkel PA, Tervaert JW, Black RM, McCluskey RT, Niles JL.

Arthritis Rheum. 1999 Feb;42(2):384-8.

37.

ANCA-positive vasculitis associated with allopurinol therapy.

Choi HK, Merkel PA, Niles JL.

Clin Exp Rheumatol. 1998 Nov-Dec;16(6):743-4.

PMID:
9844772
38.

Antineutrophil cytoplasmic antibodies in T-cell receptor alpha-deficient mice with chronic colitis.

Mizoguchi E, Mizoguchi A, Chiba C, Niles JL, Bhan AK.

Gastroenterology. 1997 Dec;113(6):1828-35.

PMID:
9394722
39.

Continuous hemofiltration.

Hsu CY, Palsson R, Niles JL.

N Engl J Med. 1997 Sep 4;337(10):713; author reply 713-4. No abstract available.

PMID:
9280826
40.

Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease.

Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL.

Ann Intern Med. 1997 Jun 1;126(11):866-73.

PMID:
9163287
41.

Comparison of anti-GBM antibodies in sera with or without ANCA.

Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C.

J Am Soc Nephrol. 1997 Mar;8(3):376-85.

42.

A renal biopsy is essential for the management of ANCA-positive patients with glomerulonephritis: the contra-view.

Niles JL.

Sarcoidosis Vasc Diffuse Lung Dis. 1996 Oct;13(3):232-4. Review. No abstract available.

PMID:
8946589
43.

The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition.

Niles JL, Böttinger EP, Saurina GR, Kelly KJ, Pan G, Collins AB, McCluskey RT.

Arch Intern Med. 1996 Feb 26;156(4):440-5.

PMID:
8607730
44.

c-ANCA as a marker of Wegener's disease.

Niles JL, McCluskey RT.

Lancet. 1996 Jan 13;347(8994):116-7; author reply 118. No abstract available.

PMID:
8538308
45.

Antineutrophil cytoplasmic antibodies in the classification of vasculitis.

Niles JL.

Annu Rev Med. 1996;47:303-13. Review.

PMID:
8712783
46.

gp330: receptor and autoantigen.

Zheng G, Bachinsky DR, Abbate M, Andres G, Brown D, Stamenkovic I, Niles JL, McCluskey RT.

Ann N Y Acad Sci. 1994 Sep 10;737:154-62. Review. No abstract available.

PMID:
7944145
47.

ANCA test in ophthalmic inflammatory disease.

Kaufman AH, Niles JL, Foster CS.

Int Ophthalmol Clin. 1994 Summer;34(3):215-27. Review. No abstract available.

PMID:
7960517
48.

Detection of two forms of GP330. Their role in Heymann nephritis.

Bachinsky DR, Zheng G, Niles JL, McLaughlin M, Abbate M, Andres G, Brown D, McCluskey RT.

Am J Pathol. 1993 Aug;143(2):598-611.

49.

Location of gp330/alpha 2-m receptor-associated protein (alpha 2-MRAP) and its binding sites in kidney: distribution of endogenous alpha 2-MRAP is modified by tissue processing.

Abbate M, Bachinsky D, Zheng G, Stamenkovic I, McLaughlin M, Niles JL, McCluskey RT, Brown D.

Eur J Cell Biol. 1993 Jun;61(1):139-49.

PMID:
8223699

Supplemental Content

Loading ...
Support Center